Patients in Europe are promised earlier access to new drugs which are showing potential, following the launch of a new scheme on Monday by the European Medicines Agency (EMA).
Through PRIME (PRIority Medicines), greater support will be given to the development of medicines targeting an unmet medical need, with the scheme focusing on drugs which offer a major therapeutic advantage over existing ones, or benefit patients with no treatment options.
These drugs are considered priority medicines within the European Union (EU).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze